Carcinoma, Transitional Cell

"Carcinoma, Transitional Cell" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.

Descriptor ID	D002295
MeSH Number(s)	C04.557.470.200.430
Concept/Terms	Carcinoma, Transitional Cell Carcinoma, Transitional Cell Carcinomas, Transitional Cell Cell Carcinoma, Transitional Cell Carcinomas, Transitional Transitional Cell Carcinoma Transitional Cell Carcinomas

Below are MeSH descriptors whose meaning is more general than "Carcinoma, Transitional Cell".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Glandular and Epithelial [C04.557.470]
Carcinoma [C04.557.470.200]
Carcinoma, Transitional Cell [C04.557.470.200.430]

Below are MeSH descriptors whose meaning is related to "Carcinoma, Transitional Cell".

Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Transitional Cell".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Carcinoma, Transitional Cell" by people in this website by year, and whether "Carcinoma, Transitional Cell" was a major or minor topic of these publications.

Bar chart showing 15 publications over 11 distinct years, with a maximum of 2 publications in 2016 and 2018 and 2021 and 2024

To see the data from this visualization as text, click here.

Year	Major Topic	Total
2005	1	1
2007	1	1
2008	1	1
2009	1	1
2011	1	1
2013	1	1
2016	2	2
2018	2	2
2019	1	1
2021	2	2
2024	2	2

Below are the most recent publications written about "Carcinoma, Transitional Cell" by people in Profiles.

Mittal K, Joshi M. Perioperative immunotherapy in urothelial carcinoma: AMBASSADOR charts the path forward. Med. 2024 Dec 13; 5(12):1449-1451.

View in: PubMed
Mittal K, Joshi M. FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape. Med. 2024 Mar 08; 5(3):176-178.

View in: PubMed
Santoni M, Myint ZW, B?ttner T, Takeshita H, Okada Y, Lam ET, Gilbert D, K?ronya Z, Tural D, Pichler R, Grande E, Crabb SJ, Kemp R, Massari F, Scagliarini S, Iacovelli R, Vau N, Basso U, Maruzzo M, Molina-Cerrillo J, Galli L, Bamias A, De Giorgi U, Zucali PA, Rizzo M, Seront E, Popovic L, Caffo O, Buti S, Kanesvaran R, Kopecky J, Kucharz J, Zeppellini A, Fiala O, Landmesser J, Ansari J, Giannatempo P, Rizzo A, Zabalza IO, Monteiro FSM, Battelli N, Calabr? F, Porta C. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study. Cancer Immunol Immunother. 2023 Sep; 72(9):2961-2970.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Massari F. Clinicopathological Features of FGFR3 - Mutated Upper Tract Urothelial Carcinoma: A Genomic Database Analysis. Clin Genitourin Cancer. 2022 10; 20(5):482-487.

View in: PubMed
Rizzo A, Mollica V, Santoni M, Ricci AD, Gadaleta-Caldarola G, Montironi R, Massari F. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis. Future Oncol. 2022 Feb; 18(6):739-748.

View in: PubMed
Aronowitz J, Ding L, Yates J, Zong Y, Zheng L, Jiang Z, Yancey J, Mittal K, Fitzgerald TJ. Stereotactic Body Radiotherapy for Palliation of Hematuria Arising From Urothelial Carcinoma of the Kidney in Unfavorable Surgical Candidates. Am J Clin Oncol. 2021 05 01; 44(5):175-180.

View in: PubMed
Sun T, Hutchinson L, Tomaszewicz K, Caporelli ML, Meng X, McCauley K, Fischer AH, Cosar EF, Cornejo KM. Diagnostic value of a comprehensive, urothelial carcinoma-specific next-generation sequencing panel in urine cytology and bladder tumor specimens. Cancer Cytopathol. 2021 07; 129(7):537-547.

View in: PubMed
Rizzo A, Mollica V, Massari F. Expression of Programmed Cell Death Ligand 1 as a Predictive Biomarker in Metastatic Urothelial Carcinoma Patients Treated with First-line Immune Checkpoint Inhibitors Versus Chemotherapy: A Systematic Review and Meta-analysis. Eur Urol Focus. 2022 Jan; 8(1):152-159.

View in: PubMed
Cimadamore A, Cheng L, Scarpelli M, Lopez-Beltran A, Mollica V, Montironi R, Massari F. Re: Alfonso G?mez de Lia?o Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76: Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. Eur Urol. 2021 01; 79(1):e17-e19.

View in: PubMed
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.

View in: PubMed

People

Explore

Similar Concepts

Top Journals